Stimulation of phosphoenolpyruvate carboxykinase (guanosine triphosphate) activity by low concentrations of circulating glucose in perfused rat liver. 1975

F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor

1. After nicotinic acid treatment, rat liver glycogen is depleted and phosphoenolpyruvate carboxykinase activity increased, to about twice the initial value. 2. The increase in phosphoenolpyruvate carboxykinase activity promoted by nicotinic acid is prevented by cycloheximide or actinomycin D, suggesting that this effect is produced by synthesis of the enzyme de novo. 3. Despite the enhancement of phosphoenolpyruvate carboxykinase activity and glycogen depletion, which occurs 5h after the injection of nicotinic acid, the gluconeogenic capacity of liver is low and considerably less than the values found in rats starved for 48h. 4. When the livers of well-fed rats are perfused in the presence of low concentrations of glucose, the activity of phosphoenolpyruvate carboxykinase significantly increases compared with the control. 5. This increase is not related to the glycogen content, but seems to be also the result of synthesis of the enzyme de novo, since this effect is counteracted by previous treatment with cycloheximide or actinomycin D. 6. Phosphoenolpyruvate carboxykinase activity is not increased in the presence of low concentrations of circulating glucose when 40 mM-imidazole (an activator of phosphodiesterase) is added to the perfusion medium. 7. Addition of dibutyryl cyclic AMP to the perfusion medium results in an increase in phosphoenolpyruvate carboxykinase activity, in spite of the presence of normal concentrations of circulating glucose. On the other hand, the concentration of cyclic AMP in the liver increases when that of glucose in the medium is low. 8. These results suggest that, in the absence of hormonal factors, the regulation of phosphoenolpyruvate carboxykinase can be accomplished by glucose itself, inadequate concentrations of it resulting in the induction of the enzyme. The mediator in this regulation, as in hormonal regulation, seems to be cyclic AMP.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008112 Liver Glycogen Glycogen stored in the liver. (Dorland, 28th ed) Hepatic Glycogen,Glycogen, Hepatic,Glycogen, Liver
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D010729 Phosphoenolpyruvate Carboxykinase (GTP) An enzyme of the lyase class that catalyzes the conversion of GTP and oxaloacetate to GDP, phosphoenolpyruvate, and carbon dioxide. This reaction is part of gluconeogenesis in the liver. The enzyme occurs in both the mitochondria and cytosol of mammalian liver. (From Dorland, 27th ed) EC 4.1.1.32. GTP-Dependent Phosphoenolpyruvate Carboxykinase,Carboxykinase, GTP-Dependent Phosphoenolpyruvate,GTP Dependent Phosphoenolpyruvate Carboxykinase,Phosphoenolpyruvate Carboxykinase, GTP-Dependent
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003513 Cycloheximide Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. Actidione,Cicloheximide
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D003994 Bucladesine A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed) Dibutyryl Adenosine-3',5'-Monophosphate,Dibutyryl Cyclic AMP,(But)(2) cAMP,Bucladesine, Barium (1:1) Salt,Bucladesine, Disodium Salt,Bucladesine, Monosodium Salt,Bucladesine, Sodium Salt,DBcAMP,Dibutyryl Adenosine 3,5 Monophosphate,N',O'-Dibutyryl-cAMP,N(6),0(2')-Dibutyryl Cyclic AMP,AMP, Dibutyryl Cyclic,Adenosine-3',5'-Monophosphate, Dibutyryl,Cyclic AMP, Dibutyryl,Dibutyryl Adenosine 3',5' Monophosphate,Disodium Salt Bucladesine,Monosodium Salt Bucladesine,N',O' Dibutyryl cAMP,Sodium Salt Bucladesine
D005260 Female Females

Related Publications

F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
November 1974, The Biochemical journal,
F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
August 1975, The Biochemical journal,
F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
May 1981, Biochemistry,
F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
May 1981, Biochemistry,
F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
December 1978, Biochemistry,
F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
June 1974, The Biochemical journal,
F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
January 1992, Bioconjugate chemistry,
F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
May 1975, The Journal of biological chemistry,
F J Moreno, and L Sánchez-Urrutia, and J M Medina, and F Sánchez-Medina, and F Mayor
September 1980, Biochimica et biophysica acta,
Copied contents to your clipboard!